Neuronetics Inc
STIM1.560USD
+0.140+9.86%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
106.77MMarket Cap
LossP/E TTM
More Details of Neuronetics Inc Company
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
Neuronetics Inc Info
Ticker SymbolSTIM
Company nameNeuronetics Inc
IPO dateJun 28, 2018
CEOMr. Keith J. Sullivan
Number of employees716
Security typeOrdinary Share
Fiscal year-endJun 28
Address3222 Phoenixville Pike
CityMALVERN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19355
Phone18776007555
Websitehttps://neurostar.com/neuronetics/
Ticker SymbolSTIM
IPO dateJun 28, 2018
CEOMr. Keith J. Sullivan
Company Executives of Neuronetics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.03M
+6410.00%
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
588.77K
+10531.00%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
570.21K
+170212.00%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
335.45K
+7554.00%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
185.35K
+7326.00%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
140.89K
+30000.00%
Mr. Mark Klausner
Mr. Mark Klausner
Managing Partner
Managing Partner
--
--
Mr. W. Andrew Macan
Mr. W. Andrew Macan
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Dr. Avinash N. Amin, M.D.
Dr. Avinash N. Amin, M.D.
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.03M
+6410.00%
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
588.77K
+10531.00%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
570.21K
+170212.00%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
335.45K
+7554.00%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
185.35K
+7326.00%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
140.89K
+30000.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Clinic revenue
21.81M
58.47%
Treatment sessions
10.76M
28.84%
NeuroStar Advanced Therapy System
3.96M
10.61%
Other
776.00K
2.08%
By RegionUSD
Name
Revenue
Proportion
United States
36.25M
97.19%
International
1.05M
2.81%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Clinic revenue
21.81M
58.47%
Treatment sessions
10.76M
28.84%
NeuroStar Advanced Therapy System
3.96M
10.61%
Other
776.00K
2.08%
Shareholding Stats
Updated: Fri, Jan 2
Updated: Fri, Jan 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Madryn Asset Management, LP
30.28%
Chernett (Jorey)
9.97%
UBS Financial Services, Inc.
3.81%
The Vanguard Group, Inc.
3.77%
BlackRock Institutional Trust Company, N.A.
3.10%
Other
49.08%
Shareholders
Shareholders
Proportion
Madryn Asset Management, LP
30.28%
Chernett (Jorey)
9.97%
UBS Financial Services, Inc.
3.81%
The Vanguard Group, Inc.
3.77%
BlackRock Institutional Trust Company, N.A.
3.10%
Other
49.08%
Shareholder Types
Shareholders
Proportion
Private Equity
30.28%
Individual Investor
19.61%
Investment Advisor
13.93%
Hedge Fund
9.59%
Investment Advisor/Hedge Fund
6.14%
Research Firm
1.71%
Bank and Trust
0.10%
Pension Fund
0.05%
Venture Capital
0.04%
Other
18.55%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
216
42.40M
61.91%
-15.44M
2025Q3
198
39.45M
57.60%
-13.65M
2025Q2
187
47.56M
71.93%
-4.03M
2025Q1
191
47.19M
71.70%
-4.84M
2024Q4
155
36.70M
70.38%
+11.74M
2024Q3
153
14.58M
47.42%
-9.85M
2024Q2
159
20.22M
66.61%
-5.87M
2024Q1
183
20.38M
68.24%
-3.49M
2023Q4
191
18.37M
63.28%
-7.87M
2023Q3
201
19.69M
68.24%
-8.69M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Madryn Asset Management, LP
20.74M
30.28%
-3.50M
-14.44%
Aug 08, 2025
Chernett (Jorey)
4.40M
6.43%
+4.40M
--
Nov 17, 2025
UBS Financial Services, Inc.
2.16M
3.16%
+1.85M
+580.70%
Sep 30, 2025
The Vanguard Group, Inc.
2.83M
4.14%
+89.50K
+3.26%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
2.12M
3.1%
+75.30K
+3.68%
Sep 30, 2025
Cucuz (Sasha)
2.03M
2.97%
+6.41K
+0.32%
Oct 20, 2025
Balyasny Asset Management LP
1.82M
2.66%
+312.55K
+20.71%
Sep 30, 2025
Sullivan (Keith J)
1.61M
2.35%
--
--
Mar 24, 2025
Wexford Capital LP
1.18M
1.72%
+534.15K
+83.06%
Sep 30, 2025
Masters Capital Management, L.L.C.
1.00M
1.46%
--
--
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AdvisorShares Psychedelics ETF
3.31%
Invesco NASDAQ Future Gen 200 ETF
0.43%
iShares Neuroscience and Healthcare ETF
0.1%
Vanguard US Momentum Factor ETF
0.04%
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.01%
Avantis US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
View more
AdvisorShares Psychedelics ETF
Proportion3.31%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.43%
iShares Neuroscience and Healthcare ETF
Proportion0.1%
Vanguard US Momentum Factor ETF
Proportion0.04%
iShares Micro-Cap ETF
Proportion0.02%
iShares Russell 2000 Growth ETF
Proportion0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
